Abstract 4650

Evolution of Expert and Healthcare Professional Treatment Recommendations in the Management of Mantle Cell Lymphoma

Amber Williams, PhD[1]; Kristen Rosenthal, PhD[1]; Stephen Ansell, MD, PhD[2]; Ian Flinn, MD, PhD[3]; Brad Kahl, MD[4]; Tycel Phillips, MD[5]; Julie Vose, MD, MBA[6]; Timothy Quill, PhD[1]

1. Clinical Education Alliance, LLC, Reston, VA. 2. Mayo Clinic Comprehensive Cancer Center, Rochester, MN. 3. OneOncology, Nashville, TN. 4. Washington University School of Medicine, Division of Oncology, St Louis, MO. 5. City of Hope National Medical Center, Duarte, CA. 6. University of Nebraska Medical Center, Omaha, NE.

Category: Health Services and Quality Improvement: Lymphoid Malignancies

Email: awilliams@cealliance.com

Background

- Recent approvals and clinical trials have established covalent BTK inhibitors (cBTKis), including ibrutinib, acalabrutinib, and zanubrutinib, as effective agents for the treatment of mantle cell lymphoma (MCL)[1]
- Additional approvals of the noncovalent BTKi pirtobrutinib and multiple CAR T-cell therapies have also advanced the management of patients who have progressed on covalent BTKi therapy

Objective

- Compare trends in MCL treatment choice among experts and healthcare professionals (HCPs) in various disease settings identified in an online treatment decision support tool

Methods

- An online treatment decision support tool, developed by 5 US-based experts in MCL, was launched in April 2023 and updated in April 2025
- The tool provided treatment recommendations for various clinical scenarios (ND or R/R disease) considering factors such as age, fitness, and previous therapies
- HCPs entered patient cases with specific characteristics along with their intended treatment choice and received 5 expert treatment recommendations for that specific scenario

Publish Date of Tool	Dates of HCP Responses	HCPs, n
4/2023	4/2023-12/2023	89
4/2025	4/2025-10/2025	74

Supported by an educational grant from AstraZeneca.

[1]NCCN. B-cell lymphomas. v.3.2025. nccn.org.

BTKi, Bruton tyrosine kinase inhibitor; cBTKi, covalent BTKi; ND, newly diagnosed; R/R, relapsed/refractory.

Results

Fig 1. Use of cBTKi for ND MCL.*

*Patients with ND MCL who are not eligible for radiation therapy.




Fig 2. Use of BOVen regimen for ND MCL* with del(17p) or *TP53*m.




Fig 3. Use of cBTKi for R/R MCL with no previous BTKi.




Fig 4. Use of CAR T-cell therapy for R/R MCL with previous BTKi.




Fig 5. Changed Intended Treatment Based on 2025 Expert Recommendations (n = 54)



Conclusion

- HCP use of BTKi therapy for MCL has increased in recent years most clearly in the newly diagnosed setting
- HCPs infrequently consider CAR T-cell therapy for R/R MCL; barriers warrant further investigation
- Decision support tools and targeted educational initiatives could help increase the use of guideline and expert treatment recommendations potentially improving patient outcomes